Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
Abstract Background Immune checkpoint inhibitors (ICIs) for solid tumors, including those targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have shown impressive clinical efficacy, however, most patients do not achieve durable responses. One major the...
Main Authors: | Jared M. Newton, Aurelie Hanoteau, Hsuan-Chen Liu, Angelina Gaspero, Falguni Parikh, Robyn D. Gartrell-Corrado, Thomas D. Hart, Damya Laoui, Jo A. Van Ginderachter, Neeraja Dharmaraj, William C. Spanos, Yvonne Saenger, Simon Young, Andrew G. Sikora |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-08-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0698-6 |
Similar Items
-
Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors
by: Svetlana Bornschlegl, et al.
Published: (2021-01-01) -
Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science
by: Ya-Shan Chen, et al.
Published: (2015-02-01) -
Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
by: Claudia Ceci, et al.
Published: (2020-11-01) -
On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
by: Benjamin Y. Kong, et al.
Published: (2019-02-01) -
Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions
by: Kamil Grubczak, et al.
Published: (2021-08-01)